Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C Byrd, Peter Hillmen, Susan O'Brien, Jacqueline C Barrientos, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger, Paul M Barr, Richard R Furman, Thomas J Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M Pagel, Jan A Burger, Jennifer A Woyach, Sandra Dai, Remus Vezan Show all
Blood | AMER SOC HEMATOLOGY | Published : 2019
Awarded by National Institutes of Health, National Cancer Institute
The authors thank the patients who participated in this study and their supportive families, as well as the investigators, subinvestigators, and coordinators at each of the study sites. The authors thank Joris Diels of Janssen and Suzy Van Sanden of HEMAR, Janssen-Cilag Ltd (Beerse, Belgium) for their work in generating the crossover-adjusted OS analysis using the rank-preserving structural failure time method. Editorial support was provided by Melanie Sweetlove and was funded by Pharmacyclics LLC, an AbbVie Company.This study was sponsored by Pharmacyclics LLC, an AbbVie Company, and Janssen Pharmaceuticals. J.C. Byrd is supported by the Four Winds Foundation, D. Warren Brown Foundation, Judy and Michael Thomas, the Sullivan CLL Research Foundation, and the National Institutes of Health, National Cancer Institute (grants R35 CA197734 and R01 CA177292).